Publications by authors named "S A Susin"
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of neoplastic CD5/CD19 B lymphocytes in the blood. These cells migrate to and proliferate in the bone marrow and lymphoid tissues. Despite the development of new therapies for CLL, drug resistance and disease relapse still occur; novel treatment approaches are therefore still needed.
View Article and Find Full Text PDFThe recognition of B-cell prolymphocytic leukemia (B-PLL) as a separate entity is controversial based on the current classification systems. Here, we analyzed the DNA methylome of a cohort of 20 B-PLL cases diagnosed according to the guidelines of the International Consensus Classification/Fourth revised edition of the World Health Organization Classification, and compared them with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), splenic marginal zone lymphoma (SMZL), and normal B-cell subpopulations. Unsupervised principal component analyses suggest that B-PLL is epigenetically distinct from CLL, MCL, and SMZL, which is further supported by robust differential methylation signatures in B-PLL.
View Article and Find Full Text PDFChronic lymphocytic leukaemia (CLL) is a heterogenous disease characterized by the accumulation of neoplastic CD5/CD19 B lymphocytes. The spreading of the leukaemia relies on the CLL cell's ability to survive in the blood and migrate to and proliferate within the bone marrow and lymphoid tissues. Some patients with CLL are either refractory to the currently available therapies or relapse after treatment; this emphasizes the need for novel therapeutic strategies that improving clinical responses and overcome drug resistance.
View Article and Find Full Text PDFArticle Synopsis
- The study explored how genetic changes impact prognosis in chronic lymphocytic leukemia (CLL) patients, focusing on the role of immunoglobulin heavy variable (IGHV) status.
- In 536 patients undergoing first-line therapies, specific genetic abnormalities like unmutated IGHV and complex karyotype were linked to shorter progression-free survival (PFS).
- The effects of these genetic factors varied based on whether patients had mutated (M-IGHV) or unmutated (UM-IGHV) IGHV, emphasizing the importance of considering IGHV status in prognosis assessments for CLL.
Background: For recurrent lumbar disc herniation, many experts suggest a repeat discectomy without stabilization due to its minimal tissue manipulation, lower blood loss, shorter hospital stay, and lower cost, recent research on the role of instability in disc herniation has made fusion techniques popular among spinal surgeons. The authors compare the postoperative outcomes of posterior lumbar interbody fusion (PLIF) and repeat discectomy for same-level recurrent disc herniation.
Methods: The patients included had previously undergone discectomy and presented with a same-level recurrent lumbar disc herniation.